Report Store Get Proposal

Home Blog Oncology 2

Oncology

pharma-news-for-astrazeneca-scholar-rock-pharming

Notizia - Recent Pharma, Healthcare and Biotech Happenings

TAGRISSO Delivers Landmark Eight-Year Survival Outcomes in Early-Stage EGFR-Mutated Lung Cancer; Scholar Rock Receives FDA Approval for ISEMBYLD; Pharming’s Joenja Receives FDA Approval as First U.S. Treatment for Children With APDS; AbbVie Reports Positive Phase 3 Results for Atogepant in Menstrual Migraine; Rezera’s Ruvonoflast Delivers Positive Inflammation Results with Favorable Safety in RESOLVE-1

TAGRISSO Demonstrates Eight-Year Landmark Survival Benefit for Patients with Early-Stage EGFR-Mutated Lung Cancer Updated exploratory findings from the Phase III ADAURA trial demonstrated that AstraZeneca’s Tagrisso (osimertinib) continued to provide a sustained and clinically meaningful overall survival (OS) benefit at eight years compared with placebo in the adjuvant treatment of patients with early-stage (IB, II, and IIIA) EGFRm NSCLC following complete tumour resection with curative intent. The findings were presented during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer (#WCLC26), organised by the International Association for ...

Explore More...

pharma-news-for-astrazeneca-argenx-bristol-myers-squibb

AstraZeneca Discontinues Phase III eVOLVE-Lung02 Trial of Volrustomig in Metastatic NSCLC; argenx Announces Favorable Topline Results from Phase 3 ALKIVIA Study of Efgartigimod; Bristol Myers Squibb’s ZENBEXUS Receives U.S. FDA Accelerated Approval in Combination with Daratumumab and Dexamethasone for Multiple Myeloma; Zealand Pharma Secures USD 100 Million in Royalty Financing Through Agreement with Royalty Pharma for Rusfertide; PTC Advances Rare Disease Strategy with Acquisition of ST-920 Fabry Disease Program

tudriqev-approval-for-melanoma

Replimune Strengthens Oncology Portfolio With TUDRIQEV Approval

Leica Biosystems Expands Digital Pathology Portfolio with Multiple FDA Clearances; Bracco’s VueJect Ultrasound Contrast Delivery System Gains FDA and Health Canada Authorizations; Oticon Introduces Next-Generation Reveal Hearing Aid With AI; Zepto Life Technology Secures Up to $8.9 Million NIAID Award for Infectious Disease Liquid Biopsy Platform; Nitinotes Broadens EASE IDE Trial Network for EndoZip; FastWave Medical Secures FDA IDE Approval for Pivotal Artero Peripheral IVL Trial

pharma-news-for-sobi-transthera-sciences-replimune

Sobi Partners with Innate Pharma to License Lacutamab for T-Cell Lymphoma; Yochanra Makes Global Debut in China as First Innovative Drug Designed to Overcome FGFR Inhibitor Resistance; Replimune Secures FDA Accelerated Approval for TUDRIQEV Plus Nivolumab in Advanced Cutaneous Melanoma; FDA Accepts Supplemental Biologics License Application for ENFLONSIA to Broaden RSV Indication in Young Children; Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals

medtech-news-for-rongtao-medical-nipro-lyric-health

Rongtao Medical Receives Prestigious Bonded Repair Authorization for Ultrasound in China; NIPRO Introduces ELISIO™-HX Expanded Hemodialysis System to U.S. Market Following FDA Clearance; Lyric Health Unveils Asynchronous Care Solution for Smarter, Connected Virtual Care; New England Biolab® Strengthens Cell-Free RNA Workflow with Monarch® Mag Cell-free RNA Extraction Kit; Aqua Medical Advances Type 2 Diabetes Research with First U.S. Patient Treated at UNC Health; MediView XR90™ Holographic Surgical Navigation System Debuts in Florida at Cleveland Clinic Weston Hospital

rise-of-intratumoral-cancer-therapy

Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer

pharma-news-for-astrazeneca-novartis-abbvie

EU Approves Datroway for First-Line Metastatic TNBC; FDA Broadens Pluvicto’s Reach with Approval in PSMA+ mHSPC; AbbVie Announces EU Authorization of RINVOQ for Severe Alopecia Areata; Novo Nordisk Announces Latest Developments from the ZEUS Phase III Trial; Replimune Secures Positive FDA Advisory Committee Vote for RP1 in Advanced Melanoma

protacs-treatment-landscape

PROTACs: An Emerging Drug Modality with Multiple Oncology Approvals Expected in the Coming Years

kras-inhibitors-beyond-g12c

Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C

pd-1-inhibitors-by-companies

PD-1 Inhibitors: Which Companies Are Winning the Immunotherapy Race?

liquid-biopsy-revolutionary-technique-for-cancer-diagnosis

Liquid Biopsy: The Blood Test That Is Redefining Cancer Diagnosis, Monitoring, And Precision Oncology

regenerative-medicine-revolution

The Regenerative Medicine Revolution: Opportunities Shaping the Next Decade

sanofi-sarclisa-escena-approval

Sanofi’s SARCLISA ESCENA Makes History as the First Wearable Cancer Treatment

drug-approvals-in-h2-2026

Top FDA Approvals to Watch in H2 2026: Regulatory Decisions Poised to Transform the Pharmaceutical Landscape

rise-of-targeted-therapeutics

The Rise of Targeted Therapeutics in Modern Healthcare

pharma-news-for-hengrui-kailera-gsk

Hengrui Pharma Encounters FDA Regulatory Hurdle for Camrelizumab–Rivoceranib; Kailera Therapeutics Announces Positive Results for HRS-7535/KAI-7535 Across Two Phase 3 Studies; Jemperli Underscores Durable Clinical Complete Responses in dMMR/MSI-H Rectal Cancer; FDA Approves PADCEV-Keytruda Combination for Neoadjuvant and Adjuvant Treatment of Muscle-Invasive Bladder Cancer; Sanofi’s Subcutaneous Sarclisa Escena Gains US Approval

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly